RPRX (Royalty Pharma plc Class A) stock: $57.91, $33.30B market cap, $837.0M cash, $41.04B EV, $24.81B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Litifilimab
Phase 3 · Active Modality: humanized IgG1 monoclonal antibody
Target BDCA2
Partnerships Biogen: sponsor/developer (Royalty Pharma funding arrangement)
Status note Royalty Pharma funding/royalty interest; humanized IgG1 monoclonal antibody targeting BDCA2. Variable quarterly payments commenced Q2 2026.
Olpasiran
Phase 3 · Active Modality: siRNA
Target lipoprotein(a)
Partnerships Amgen: sponsor/developer (Royalty Pharma funding arrangement)
Indications- elevated lipoprotein(a) (Phase 3)
Status note Royalty Pharma funding/royalty interest; small interfering RNA for elevated Lp(a).
Omecamtiv mecarbil
Phase 3 · Active Modality: small molecule
Target cardiac myosin
Partnerships Cytokinetics: sponsor/developer (Royalty Pharma expanded funding collaboration, $100M for Phase 3)
Indications- heart failure with severely reduced ejection fraction (Phase 3)
Status note Royalty Pharma funding/royalty interest; cardiac myosin activator.
Pelacarsen
Phase 3 · Active Modality: antisense oligonucleotide
Target lipoprotein(a)
Partnerships Novartis: sponsor/developer (Royalty Pharma funding arrangement)
Indications- elevated lipoprotein(a) (Phase 3)
Status note Royalty Pharma funding/royalty interest; antisense oligonucleotide for elevated Lp(a).
Seltorexant
Phase 3 · Active Modality: small molecule
Target orexin 2 receptor
Partnerships Johnson & Johnson: sponsor/developer (Royalty Pharma funding arrangement)
Indications- major depressive disorder with insomnia symptoms (Phase 3)
Status note Royalty Pharma funding/royalty interest; selective orexin 2 receptor antagonist.
Frexalimab
Phase 3 · Active Modality: monoclonal antibody
Target CD40 ligand
Partnerships Sanofi: sponsor/developer (Royalty Pharma funding arrangement)
Indications- multiple sclerosis (Phase 3)
Status note Royalty Pharma funding/royalty interest; anti-CD40 ligand monoclonal antibody.
Regulatory filing stage interests
Phase 3 · Active
Partnerships Nuvalent (neladalkib), Zenas BioPharma (obexelimab), Novartis (pelabresib), Emalex Neuroscience (ecopipam)
Indications- ALK mutation-positive non-small cell lung cancer (Phase 3)
- IgG4-related disease (Phase 3)
- myelofibrosis (Phase 3)
- Tourette's syndrome (Phase 3)
Catalysts- — first half of 2026
- — second quarter of 2026
- — 2026
- — 2026
Status note Royalty Pharma funding/royalty interests at or approaching regulatory filing: neladalkib (next-generation ALK TKI, FDA filing H1 2026), obexelimab (bifunctional CD19/FcγRIIb antibody, FDA filing Q2 2026), pelabresib (BET inhibitor, EMA filing 2026), ecopipam (oral dopamine-1 antagonist, FDA filing 2026).
TEV-'749
Phase 3 · Active Modality: long-acting subcutaneous injection
Partnerships Teva: sponsor/developer (Royalty Pharma funding arrangement)
Status note Royalty Pharma funding/royalty interest; long-acting subcutaneous injection of olanzapine; FDA approval expected H2 2026.
Tividenofusp alfa
Phase 3 · Active
Partnerships Denali: sponsor/developer (Royalty Pharma funding arrangement)
Status note Royalty Pharma funding/royalty interest in this Denali program; PDUFA date April 5, 2026.
TEV-'408
Phase 2 · Active Modality: monoclonal antibody
Target IL-15
Partnerships Teva: R&D funding agreement (Q1 2026; up to $500M — co-fund Phase 2b vitiligo up to $75M, option for up to $425M Phase 3)
Indications- vitiligo and other autoimmune conditions (Phase 2)
Status note Royalty Pharma R&D funding interest; anti-IL-15 antibody. Co-funding a Phase 2b study in vitiligo.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.